References
- Moertel C.G., Fleming T.R., MacDonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., Veeder M.H., Mailliard J.A. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 1990; 322: 352–358
- Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990; 264: 1444–1450
- Takimoto C.H. Enigma of fluorouracil and levamisole. J. Natl Cancer Inst. 1995; 87: 471–473
- Zalcberg J.R., Siderov J., Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. Ann. Oncol. 1996; 7: 41–46
- Wolmark N., Rockette H., Mamounas E., Jones J., Wieand S., Wickerham D.L., Bear H.D., Atkins J.N., Dimitrov N.V., Glass A.G., Fisher E.R., Fisher B. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J. Clin. Oncol. 1999; 17: 3553–3559
- Haller D.G., Catalano P.J., MacDonald J.S. Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: five-year final report of INT-0089. Proc. Am. Soc. Clin. Oncol. 1998; 17: 982
- Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457–481
- Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 1966; 50: 163–170
- Buyse M., Zeleniuch-Jacquotte A., Chalmers T.C. Adjuvant therapy of colorectal cancer, why we still don't know. JAMA 1988; 259: 3571–3578
- Gray R., James R., Mossman J., Stenning S. Axis-a suitable case for treatment. Br. J. Cancer 1991; 63: 851–855
- Buroker T.R., Moertel C.G., Fleming T.R., Everson L.K., Cullinan S.A., Krook J.E., Mailliard J.A., Marschke R.F., Klaassen D.J., Laurie J.A. A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J. Clin. Oncol. 1985; 3: 1624–1628
- Arnaud J.P., Buyse M., Nordlinger B., Martin F., Pector J.C., Zeitoun P., Adloff A., Duez N. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br. J. Surg. 1989; 76: 284–289
- Haller D.G. An overview of adjuvant therapy for colorectal cancer. Eur. J. Cancer 1995; 31A: 1225–1263
- Bandealy M.T., Gonin R., Loherer P.J., Monaco F., Einhorn L.H. Prospective randomized trial of 5-fluorouracil versus 5-fluorouracil plus levamisole in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group Trial. Clin. Cancer Res. 1998; 4: 935–939
- Grage T.B., Moss S.E. Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospective controlled randomized trial. Surg. Clin. N. Am. 1981; 61: 1321–1329
- Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995; 345: 939–944
- Laurie J.A., Moertel C.G., Fleming T.R., Willand H.S., Leigh J.E., Rubin J., McCormack G.W., Gerstner J.B., Kwok J.E., Mailliard J., Twito D.I., Morton R.F., Tschetter L.K., Barlow J.F. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J. Clin. Oncol. 1989; 7: 1447–1456
- Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000; 355: 1588–1596
- O'Connel M.J., Laurie J.A., Kahn M., Fitzgibbons R.J., Erlichman C., Sheperd L., Moertel C.G., Kocha W.I., Pazdur R., Wieand H.S., Rubin J., Vukov A.M., Donohue J.H., Krook J.E., Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol. 1998; 16: 295–300